Chairman, American Living Organ Donor Fund, Ambassador and Rare Disease Patient,
Patient-Center Outcomes Research Institute (PCORI)
Conference Day Two
Wednesday, November 6th, 0019
The collection and use of Real World Data divides opinion, not just within the pharmaceutical industry but also between stakeholders. Join us as we demonstrate the diverse perspectives of various stakeholders as we debate the value of Real World Evidence.
The human spectrogram allows all delegates to present their view on this contentious topic by voting with their feet. At the start of the debate, delegates will move to the corner of the room that most aligns with their view on Real World Evidence. We will then conduct the debate. Following the panel discussion, the delegation will be invited to vote again, allowing us to reflect on how our views have changed.
Topics of Discussion:
- Consider the perspective of multiple stakeholders in the collection of real world evidence
- Understand how this information can be contextulised in a wider clinical trial via the integration of data in a combined study approach
- Explore how real world evidence affects later submissions for re-imbursement
Post-Conference Workshop Day
Thursday, November 7th, 0019
9:30 AM Patient Perspective: Maximising Patient Engagement Across the Time-Line of an Early Access Programme
Patients are at the heart of every Early Access Programme. With growing influence in the development of regulatory guidelines, now is the time to engage your patients in the evolution of your Early Access Programme.
Explore the benefits of patient-centricity across the timeline of an Early Access Programme, deep-diving into the opportunities that arise by bringing the voice of the patient to the development of future programmes, with respect to commercialisation and market access strategies.
- Improve your understanding of how patient engagement helps shape market access as part of your commercialization strategy
- Highlight the benefits of working collaboratively with patients at the preparatory stages of your Early Access Programme, with the view to maximize patient uptake
- Analyse the positive business implications of patient engagement beyond your Early Access Programme and the clinical trial by cooperating on close-out planning
- Explore the work of PCORI within the industry and analyse the growing influence of Patient Advocacy groups and patients on regulatory change